Trichomonas vaginalis RNA, Qualitative, TMA
Also known as: Trichomoniasis, T.vaginalis, T vaginalis, Vaginitis, Trichomonas Vaginalis RNA
Use
This transcription‑mediated amplification (TMA) assay is a highly sensitive and specific NAAT method for detecting Trichomonas vaginalis rRNA in clinical samples, outperforming traditional methods (e.g., wet mount, culture). Sensitivity approaches 100% for vaginal and endocervical swabs and 90–95% for urine, with specificity near 100%. It is FDA cleared and suitable for detection of the parasite from female urogenital specimens.
Special Instructions
Utilizes the SureSwab® collection system into an Aptima™ transport tube which releases and stabilizes rRNA. After target capture and washing, TMA amplifies a region of 16S rRNA; detection is via chemiluminescent DNA probe hybridization. Performed using Hologic® TMA technology.
Limitations
Slightly reduced sensitivity (90–95%) when using urine specimens compared to swabs. Performance relies on proper specimen collection and handling. Traditional methods have lower sensitivity, but limitations include that this molecular assay detects rRNA and may not distinguish viable organisms.
FDA Approved
Methodology
PCR-based (Other)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Cervical Swab
Volume
Not provided
Minimum Volume
Not provided
Container
Aptima Transport Tube
Storage Instructions
Room Temperature